Jamie Blundell
@jamie-blundell.bsky.social
Evolution, cancer, immunology, math(s)
Ursula Zoellner Professor of Cancer Research
University of Cambridge
blundelllab.com
Ursula Zoellner Professor of Cancer Research
University of Cambridge
blundelllab.com
Thank you Vijay!
January 21, 2025 at 8:33 PM
Thank you Vijay!
This idea -- Somatic variants as an in vivo saturation mutagenesis screen — opens up so many opportunities too. # cells >> # people, so you get more statistical power and you preserve cell context (i.e. specific to T-cells here). They have opened up the world of somatic, tissue specific GWAS…
December 27, 2024 at 3:21 PM
This idea -- Somatic variants as an in vivo saturation mutagenesis screen — opens up so many opportunities too. # cells >> # people, so you get more statistical power and you preserve cell context (i.e. specific to T-cells here). They have opened up the world of somatic, tissue specific GWAS…
For me it is "Naturally occurring T cell mutations enhance engineered T cell therapies"
The idea is so simple: use naturally occurring somatic mutations as an in vivo screen. Evolution finds mutations that improve T-cell persistence and survival which would not have been discovered with CRISPR.
The idea is so simple: use naturally occurring somatic mutations as an in vivo screen. Evolution finds mutations that improve T-cell persistence and survival which would not have been discovered with CRISPR.
Naturally occurring T cell mutations enhance engineered T cell therapies - Nature
A study examines the effects of mutations that occur naturally in T cell cancers, reporting that such mutations can potentially be exploited to increase the potency of T cell therapies.
www.nature.com
December 27, 2024 at 3:21 PM
For me it is "Naturally occurring T cell mutations enhance engineered T cell therapies"
The idea is so simple: use naturally occurring somatic mutations as an in vivo screen. Evolution finds mutations that improve T-cell persistence and survival which would not have been discovered with CRISPR.
The idea is so simple: use naturally occurring somatic mutations as an in vivo screen. Evolution finds mutations that improve T-cell persistence and survival which would not have been discovered with CRISPR.
Landmark moment for early cancer detection 🤩👏👏👏
November 29, 2024 at 12:57 PM
Landmark moment for early cancer detection 🤩👏👏👏